The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reading Rheum

Reading Rheum

September 1, 2007 • By Gail C. Davis, RN, EdD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Opioids are increasingly used to treat chronic pain. They offer a viable option for many patients who either have side effects (e.g., gastrointestinal upset and kidney damage) associated with the use of nonsteroidal antiinflammatories (NSAIDs) or are not attaining a level of relief that supports a desirable level of function. In some cases, opioids may be combined with an NSAID or a disease-modifying antirheumatic drug (DMARD) for treatment.

You Might Also Like
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum
Explore This Issue
September 2007
Also By This Author
  • Pain Management Meditations

The open-label study reviewed here was conducted with 226 patients from 55 private practices in Germany. All participants had a diagnosis of RA as defined by the ACR criteria. Their initial pain rating was 6 or greater on an 11-point scale; none had been previously treated with transdermal fentanyl, but 38 were taking another opioid. Transdermal fentanyl was started at 25 µg/h in 192 patients (85%), 50 µg/h in 33 patients (14.5%), and 75 µg/h in one patient, and 180 (80%) completed the study protocol.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients stopped taking other opiods prior to entering the study but continued other pharmacological (e.g., glucocorticoids, NSAIDs, and methotrexate) and nonpharmacological therapy (e.g., exercise).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
click for large version

The study results showed significant improvement in pain intensity, sleep quality, activities, treatment satisfaction, and perceived general well-being. All variables other than pain intensity were measured on 5-point scales. (See Table 1)

There were a total of 75 adverse events in 39 (17%) of the patients. The most common were nausea (22%) and vomiting (16%). Few (1.3%) experienced constipation, which is generally acknowledged as an issue related to the use of opioids.2

About half of the sample (58%) agreed to be contacted at the end of six and 12 months to determine whether the initial study findings remained stable. The mean dose of fentanyl for this subgroup had increased from 28.8 µg/h at the end of 30 days to 49.1 µg/h at the end of 12 months. With this moderate increase in dose, all of the findings remained stable.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The study’s findings do indicate that transdermal fentanyl might be given consideration for pain management, as well as management of other symptoms (e.g., sleep quality and function) and of overall quality of life (e.g., coping with daily demands and feeling content). This is in keeping with the American Pain Society’s recommendation that “Opioids should be used for patients with OA and RA when other medications and nonpharmacologic interventions produce inadequate pain relief and the patient’s quality of life is affected by the pain.”2

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis Tagged With: Fentanyl, Pain, Patients, Reading Rheum, Research, Rheumatoid arthritisIssue: September 2007

You Might Also Like:
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)